“In spinal cord injury, even a mild improvement can make a significant difference in that patient’s quality of life”.
–Dr Mohamad Bydon, Mayo Clinic researcher
Adipose tissue has been the most studied type and form of tissue structure since the last decade. Its endocrine abilities can extend in taking part in a complex networking of the endocrine, nervous and cardiovascular systems.
Adipose tissue-derived stem cells known as ADSCs are part of a larger group of mesenchymal stem cells (MSCs), they are obtained either from the subcutaneous tissue of the abdomen, thigh, and arm. There are utilised for the treatment of conditions like, spinal cord injuries, diabetes mellitus, liver disease, corneal lesions, articular and cutaneous lesions.
It is also capable of regenerating motor and sensory functions of patients under certain conditions like stroke, Alzheimer’s disease, Parkinson’s disease, peroneal nerve injuries. It is additionally used as an aid in adjunction to autologous nerve graft. Advantages of ADSCs are; its easy to access and harvest, the procedure isn’t as painful as the bone marrow one, and its use doesn’t cause that much controversies regarding ethics.
Its endocrine activity involves the release of factors in the body like adipoctyokines, cytokines, transcriptional and growth factors, which forms a secretome. A secretome is a collective group of molecules and biological factors that are secreted in the extracellular matrix. According to Gimble et al., five molecules must be incorporated for the medical use of these cells; firstly, cells must be present abundantly, secondly, harvesting is done through minimal invasive procedures, thirdly, differentiation of cell lineages must be ensured, fourth, autograft made possible, and last but not least, fifth, manipulation of its use in professional practice.
In 2nd April, 2024, a scientific discovery was made, that adipose stem cell therapy could potentially be used for treatment of nerve injury. A man named Chris Barr, a victim of a surfing accident was paralysed from neck to feet. He was part of the Mayo Clinic Phase 1 study that was initiated from 2018. Here, the stem cells were derived from his stomach fat, expanded to a 100 million cells in a laboratory and eventually injected back to his lumbar spine.
The success is not just limited to Chris but to other nine more patients as well. The therapy that took more than five years has enabled himself to become more mobile and perform day-to-day activities independently!
Nivea Vaz
Manipal College of Medical Sciences, Pokhara







Leave a comment